PaO2

DCGI gives Nod for Restricted Emergency Use to Itolizumab for moderate to severe COVID-19 patients

Itolizumab (rDNA origin), a monoclonal antibody which was already approved for severe chronic plaque psoriasis, has now been granted Restricted…

Read More »